NCT04690335View on ClinicalTrials.gov

Human Challenge Study to Evaluate the Efficacy of MV-012-968 Vaccine

PHASE2CompletedINTERVENTIONAL
Enrollment

60

Participants

Timeline

Start Date

December 29, 2020

Primary Completion Date

May 7, 2021

Study Completion Date

September 9, 2021

Conditions
RSV Infection
Interventions
BIOLOGICAL

MV-012-968

MV-012-968 is a recombinant, live attenuated RSV vaccine.

OTHER

Placebo

Saline solution

Trial Locations (1)

E1 2AX

hVIVO Services Ltd, London

Sponsors

Collaborators (1)

Hvivo
All Listed Sponsors
collaborator

Hvivo

INDUSTRY

lead

Meissa Vaccines, Inc.

INDUSTRY

NCT04690335 - Human Challenge Study to Evaluate the Efficacy of MV-012-968 Vaccine | Biotech Hunter | Biotech Hunter